Skip to main content

Table 1 Clinical inputs parameter estimates

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameter Annual probabilities
Non-prophylaxis Source Palivizumab Source
Probability of hospital admission due RSV infection
 Total population 4.10% [14] 1.30% [14]
 Subgroup A 18.40% [33] 9.50% [33]
 Subgroup B 10.60% 3.60%
 Subgroup C 10.20% 2.90%
Probability of emergency visits prior to hospital admission
  17.80% [14] 17.80% [14]
Probability of death related to hospital admission
  2.33% [3] 2.33% [3]
Probability of additional hospitalizations due to new RSV infection
  2.47% [14] 2.47% [14]
Probability of recurrent wheezing in hospitalized patients.
 Year 2 41.43% [15] 18.43% [15]
 Year 3 29.27% 11.05%
 Year 4 18.55% 6.12%
 Year 5 15.00% 4.39%
 Year 6 12.39% 3.25%
Probability of recurrent wheeze in no-hospitalized patients
 Year 2 12.09% [15] 5.38% [15]
 Year 3 15.36% 5.80%
 Year 4 12.57% 4.15%
 Year 5 9.31% 2.73%
 Year 6 9.66% 2.53%
  1. Subgroup A includes preterm infants with 2 major risk factors and 2 minor risk factors; subgroup B, 2 major risk factors and 1 minor risk factors; subgroup C, 2 major risk factors [33]
  2. Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender